# Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer

> **NCT02474173** · PHASE1 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 31 (actual)

## Conditions studied

- Advanced Breast Carcinoma
- Metastatic Breast Carcinoma
- Stage III Breast Cancer AJCC v7
- Stage IIIA Breast Cancer AJCC v7
- Stage IIIB Breast Cancer AJCC v7
- Stage IIIC Breast Cancer AJCC v7
- Stage IV Breast Cancer AJCC v6 and v7
- Triple-Negative Breast Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Onalespib
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT02474173
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01-15
- **Primary completion:** 2022-10-26
- **Final completion:** 2022-10-26
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Drug supply issues
- **Last updated:** 2022-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02474173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02474173, "Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02474173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*